pramipexole IR / Generic mfg. - LARVOL DELTA

What's Hot, What's Not: Review of Pharmacological Options for Managing Burning Mouth Syndrome. (PubMed, Ann Pharmacother) - "Multiple agents with different mechanisms of action may be beneficial in the management of BMS. In the absence of treatment guidelines, providers may refer to this review when managing their patients."

Journal • Review • Pain

Deciphering the Role of NLRP-3/Caspase-1/GSDMD Pyroptotic Signal, miR-675-5p, and miR-1247-5p in Mitigation of Neurobehavioral and Neuropathological Alterations in Rotenone-Induced Striatal Neurodegeneration by Vitex agnus-castus Leaf Extract and/or Pramipexole in Male Rats. (PubMed, Mol Neurobiol) - "The combined therapy showed an improvement in striatal histoarchitecture with mitigation of caspase-1 and glial fibrillary acidic protein immunoreactivity with an upregulation in synaptophysin immunoreactivity. In conclusion, the combined therapy of Vitex A-C and Prami holds a promising therapeutic avenue over them alone against ROT-associated striatal neurodegeneration via inhibiting the pyroptotic pathway."

Journal • Preclinical • CNS Disorders • AIF1 • CASP9 • CAT • GFAP • GSDMD • HMGB1 • IL18 • IL1B • MIR1247 • MIR675 • NLRP3 • SYP

Levodopa/carbidopa/entacapone versus levodopa/benserazide plus pramipexole in Chinese patients with Parkinson's disease experiencing wearing off. (PubMed, Front Neurol) - "One patient in the LCE group and 2 patients in the PPX group experienced mild dyskinesia. LCE and LB + PPX were both effective, safe and tolerable in treating patients with PD who experienced WO."

Journal • CNS Disorders • Depression • Movement Disorders • Parkinson's Disease • Psychiatry

Cost-effectiveness of pramipexole augmentation for acute phase and maintenance therapy of treatment-resistant depression compared to placebo augmentation: economic evaluation of the PAX-D randomised controlled trial. (PubMed, Lancet Reg Health Eur) - P4 | "Further trials, directly comparing pramipexole to other augmentation strategies, will be useful in determining the position of this repurposed medication in the treatment pathway of depression. National Institute for Health and Care Research, Efficacy and Mechanism Evaluation Programme."

HEOR • Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Streamlined spectrofluorimetric assay for Pramipexole using acid red 87 quenching strategy for tablet and uniformity evaluation. (PubMed, Sci Rep) - "Comprehensive validation studies, conducted in accordance with International Council for Harmonisation (ICH) guidelines, confirmed the method's reliability. The validated approach was subsequently applied successfully to assay PPX in pharmaceutical tablets and to evaluate tablet content uniformity."

Journal • CNS Disorders • Movement Disorders • Restless Legs Syndrome

Psychiatric Comorbidities in Parkinson's Disease: A Moroccan Perspective on Anxiety and Depression. (PubMed, Diseases) - "L-DOPA alone was used to treat half of the patients, while combinations of Trivastal, Sifrol, anticholinergics, or antidepressants were given to the other half. Regardless of the method of treatment or stage of the disease, psychiatric symptoms are prevalent. For PD patients to benefit from early interventions and achieve an improved quality of life, routine screening is crucial."

Journal • CNS Disorders • Depression • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Single-dose,First-in-human of KLA478 (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Hunan Kelun Pharmaceutical Co., Ltd.

First-in-human • New P1 trial

Nocturnal Hypokinesia and Early Morning OFF in Parkinson's Disease: State-of-the-Art and Systematic Review of Treatment Availability. (PubMed, Curr Neurol Neurosci Rep) - "Pharmacologic treatments include standard and sustained-release levodopa, dopamine agonists (rotigotine, ropinirol, pramipexole, and apomorphine), MAO-B inhibitors (rasagiline, safinamide), COMT inhibitors (opicapone), and rescue therapies like inhaled or dispersible levodopa or apomorphine injection. For mild, disturbing symptoms in early PD, inhaled or dispersible levodopa or apomorphine injection are advised. In moderate to advanced stages, treatment options include long-acting dopamine agonists, MAO-B inhibitors, sustained-release levodopa, or COMT inhibitors selected based on factors such as daytime motor symptoms, and non-motor symptoms."

Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

Case Report: Near-fatal adverse effects of dopamine agonist for the treatment of restless legs syndrome. (PubMed, Front Pharmacol) - "Dopamine agonists such as pramipexole are commonly prescribed for the treatment of restless legs syndrome; however, growing recognition of potential serious adverse effects has led to updated clinical guidelines which now recommend against the routine use of dopamine agonists as initial therapy...Her condition improved following medication taper, appropriate management of restless legs syndrome, and acute psychiatric interventions. Clinicians should be aware of the potential adverse effects associated with dopamine agonists and adhere to updated recommendations for the management of restless legs syndrome."

Adverse events • Journal • Movement Disorders • Pain • Psychiatry • Restless Legs Syndrome • Sleep Disorder • Suicidal Ideation

Managing Constipation in Older Adults on Atypical Antipsychotics: A Defecation Reflex and Gut Microbiota Approach. (PubMed, Psychogeriatrics) - "This intervention may restore central dopaminergic function, thereby strengthening the compromised defecation reflex. This integrated framework-addressing monoaminergic and gut microbiota mechanisms-provides a more complete understanding for future research and clinical strategies."

Journal • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Pain

Pramipexole is a DA receptor agonist that induce dopaminergic gene expresión and madure SH-SY5Y neurons (Neuroscience 2025) - "To date, the activity of PXL on dopaminergic gene expression has not been reported. We report la activity of PXL on gene expresión of DAT, TH, Nurr1 and BDNF and its capacity of induce madure SH-SY5Y neurons."

CNS Disorders • Movement Disorders • Parkinson's Disease • BDNF • NR4A2

Pramipexole hyperactivates the external globus pallidus and impairs decision-making in a mouse model of Parkinson's Disease (Neuroscience 2025) - "These findings demonstrate that the hyperactivation of GPe neurons in the indirect pathway impairs decision-making in PD model mice. The results provide a candidate mechanism and therapeutic target for pathological gambling observed during D2/D3 receptor pharmacotherapy in PD patients."

Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease • FOS

miR-10a-5p Modulates Impulsive Choice in Rats: Insights into the Role of PI3K and the AKT/MTOR Pathway (Neuroscience 2025) - "Results obtained from NGS sequencing of miRNA-enriched fractions show that under sub chronic administration of pramipexole, a drug used for the treatment of human PD, the expression of miR-10a-5p is increased in the dorsal medial striatum and the nucleus accumbens (NAc) of highly impulsive rats in DDT...In summary, our findings suggest that miR-10a-5p directly promotes impulsive behaviors, potentially through its interaction with PI3K. Future studies will investigate other molecular targets, as well as the role of miR-10a-5p in compulsive behaviors."

Preclinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Mental Retardation • Movement Disorders • Parkinson's Disease • Psychiatry • PTEN

Evaluation of the elevated plus maze to assay risk-based decision making (Neuroscience 2025) - "Diazepam increased % open arm time [F(1,34)=12.82, p=0.001], reproducing typical EPM findings and validating our pramipexole findings. Thus, the EPM does not measure RBDM as seen in the clinic. Clinically translatable operant paradigms (e.g., rodent Iowa Gambling Task) remain the gold standard for preclinical study of RBDM."

Late-breaking abstract • CNS Disorders • Mental Retardation • Mood Disorders • Psychiatry

Dopaminergic denervation in the rat external globus pallidus produces thermal and mechanical allodynia that is reversed by pramipexol. (Neuroscience 2025) - "In conclusion, the GP participates in pain response and administering a D2/D3 agonist such as pramipexole can reverse the allodynia caused by dopamine reduction. The pain response observed in PD may be due to a reduction of dopamine at the GP level."

Late-breaking abstract • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Pramipexole-Induced Hyponatremia: A Rare but Potentially Symptomatic and Treatment-Resistant Effect at Low Doses (KIDNEY WEEK 2025) - "This can prolonged hospital stays and increased morbidity. Therefore, in patients taking pramipexole who present with hyponatremia—regardless of dosage—clinicians should maintain a high index of suspicion and consider prompt evaluation and potential discontinuation of the medication as part of the treatment strategy."

Atrial Fibrillation • Cardiovascular • Heart Failure • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Squamous Cell Carcinoma • Vulvar Cancer

Dopamine agonist treatment normalizes neck motor dyscoordination and relieves pain in chronic tension-type headache and common whiplash. A pilot study. (PubMed, Pain Manag) - P4 | "Fifteen patients, comprising 8 tension-type headache and 7 common whiplash patients, all with significant neck muscle tenderness, were started on a standard Pramipexole treatment by 0.18 mg Pramipexole daily and increased by 0.18 mg weekly to 0.18 mg × 3 daily for maintenance...This result provides preliminary support of the hypothesis of a pathogenetic relation between the dyssynergic neck muscle innervation and pain in TTH and common WL. EudraCT 2021-003574-31."

Journal • Ataxia • Musculoskeletal Pain • Pain

Preparation and Optimization of Pramipexole Hydrochloride Solid Dispersions to Improve Drug Release and Bioavailability. (PubMed, AAPS PharmSciTech) - "Thus, PPX-SD exhibited a sustained-release and markedly improved the bioavailability by maintaining supersaturated amorphous substances, inhibiting precipitation during the drug absorption phase. This formulation offers a robust scientific foundation for the treatment of Parkinson's disease."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

The effects of RBD medications on dream content: A critical review of evidence. (PubMed, Sleep Med) - "This systematic review critically evaluates the literature on the effects of medications commonly used in REM sleep behavior disorder and Parkinson's disease - including clonazepam, other benzodiazepines, melatonin, melatonin receptor agonists, levodopa, pramipexole, and other dopamine agonists - on dream content. This review highlights the need for rigorously controlled studies using standardized and reproducible methods to clarify the role of pharmacological treatments in shaping dream content in REM sleep behavior disorder. Future research should also integrate retrospective and prospective data-collection designs to account for potential recall biases."

Journal • Review • CNS Disorders • Mental Retardation • Movement Disorders • Parkinson's Disease • Psychiatry • REM Sleep Behavior Disorder • Sleep Disorder

Remarkable therapeutic effects of methylphenidate in periodic limb movement disorder comorbid with excessive daytime sleepiness: a case report. (PubMed, Front Neurosci) - "Initially, we used levodopa 250 mg per night for 12 weeks, then piribedil 50 mg per night was arranged as the second drug for 12 weeks, and the third drug, pramipexole, was prescribed at a dosage of 0.25 mg per night for 12 weeks, but the EDS was persistent despite the periodic leg movement index (PLMI) returning to normal. A 2.5-year follow-up was scheduled for taking methylphenidate; the symptoms of EDS were steadily well controlled, and PLMI was still kept in the normal range. This finding suggests that methylphenidate is an optimal therapeutic approach for the management of PLMD comorbid EDS."

Journal • Excessive Daytime Sleepiness • Movement Disorders • Sleep Disorder

Dopamine Agonist Pramipexole Halts Leflunomide Nephrotoxicity: A Dual Strike on TLR4-Driven Inflammation and PI3K/Akt Suppression. (PubMed, Eur J Pharmacol) - "The reversal of pramipexole's effects by Wortmannin confirmed the central role of PI3K/Akt signaling. These findings highlight pramipexole as a promising nephroprotective agent capable of counteracting leflunomide-induced renal toxicity through coordinated modulation of inflammatory and oxidative pathways."

IO biomarker • Journal • Immunology • Inflammation • Nephrology • Renal Disease • BAX • BCL2 • CASP3 • CD4 • IL17A • MYD88 • TLR4 • TRAF6

Pramipexole improves cognitive deficits and synaptic plasticity impairments in 3xTg-AD mice through enhancing autophagy. (PubMed, Exp Neurol) - "Bioinformatics analysis identified MAPK1 as a key target in PPX-ameliorated AD by enhancing autophagy. These findings suggest that PPX alleviates AD-related cognitive deficits and neuropathologies through increased autophagy, emphasising its potential as a disease-modifying therapeutic strategy for AD."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Psychiatry • BECN1 • DLG4 • MAPK1

Survey of knowledge and training needs of professionals in nursing homes for Parkinson's disease (MDS Congress 2025) - "In addition, dopaminergic agonists are little known to professionals (Sifrol 25% and Requip 21%). Nursing home professionals are familiar with certain aspects of Parkinsonian syndromes. In view of the results obtained, work needs to be undertaken to adapt to specific specific requests, in order to promote expertise towards Parkinsonian patients."

CNS Disorders • Depression • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Medication therapy in Parkinson's disease patients: a cross-sectional study at the University Medical Center at Ho Chi Minh City, Vietnam (MDS Congress 2025) - "A total of 177 patients (81.2%) used the dopamine agonist (pramipexole) with a median dose of 0.75 mg... Levodopa was the drug most commonly prescribed to treat motor symptoms in patients with Parkinson's disease. Combination therapy with levodopa and a dopamine agonist was most commonly used. Drug-induced motor complications were common in Parkinson's disease."

Clinical • Observational data • CNS Disorders • Movement Disorders • Parkinson's Disease

Pathogenic TBK1 Mutation Associated with Multiple System Atrophy-Like Phenotype (MDS Congress 2025) - "Trials of carbidopa/levodopa, ropinirole, pramipexole, and amantadine had minimal clinical benefit. Exome sequencing revealed a heterozygous nonsense mutation (c.1335 G>A; p.W445*) in exon 11 of TBK1, predicted to cause protein truncation or nonsense-mediated decay. This specific mutation has been reported in patients with FTD and one case of FTD-CBS (4,5). Soon after, patient developed severe stridor with vocal cord paralysis and worsening orthostatic hypotension requiring hospitalization and ultimately declined life-sustaining interventions."

Alzheimer's Disease • Ataxia • Behavior Disorders • CNS Disorders • Dementia • Dystonia • Frontotemporal Lobar Degeneration • Mental Retardation • Movement Disorders • Multiple System Atrophy • Parkinson's Disease • Progressive Supranuclear Palsy • Psychiatry • TBK1